190 related articles for article (PubMed ID: 37410332)
1. Statin Intolerance: an Overview of US and International Guidance.
Cheeley MK; Clegg K; Lockridge C; Schubert TJ; Jones LK
Curr Atheroscler Rep; 2023 Aug; 25(8):517-526. PubMed ID: 37410332
[TBL] [Abstract][Full Text] [Related]
2. Statin associated muscle symptoms (SAMS): strategies for prevention, assessment and management.
Iatan I; Mancini GBJ; Yeoh E; Hegele RA
Expert Rev Cardiovasc Ther; 2023 Jun; 21(6):423-435. PubMed ID: 37212306
[TBL] [Abstract][Full Text] [Related]
3. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient.
Cheeley MK; Saseen JJ; Agarwala A; Ravilla S; Ciffone N; Jacobson TA; Dixon DL; Maki KC
J Clin Lipidol; 2022; 16(4):361-375. PubMed ID: 35718660
[TBL] [Abstract][Full Text] [Related]
4. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
5. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Trends in Statin Therapy for Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults From 2007 to 2016.
Yao X; Shah ND; Gersh BJ; Lopez-Jimenez F; Noseworthy PA
JAMA Netw Open; 2020 Nov; 3(11):e2025505. PubMed ID: 33216139
[TBL] [Abstract][Full Text] [Related]
7. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
Chapman MJ; Zamorano JL; Parhofer KG
Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns of lipid-lowering therapies and possible statin intolerance among statin users with clinical atherosclerotic cardiovascular disease (ASCVD) or diabetes mellitus (DM) in Taiwan.
Chen WJ; Wen YC; Fox KM; Shen LJ; Lin LY; Qian Y; Zhao Z; Rane PP; Hsiao FY
J Eval Clin Pract; 2020 Aug; 26(4):1171-1180. PubMed ID: 31646715
[TBL] [Abstract][Full Text] [Related]
9. Statin-Associated Muscle Disease: Advances in Diagnosis and Management.
Taylor BA; Thompson PD
Neurotherapeutics; 2018 Oct; 15(4):1006-1017. PubMed ID: 30251222
[TBL] [Abstract][Full Text] [Related]
10. Expert opinion: the therapeutic challenges faced by statin intolerance.
Patel J; Martin SS; Banach M
Expert Opin Pharmacother; 2016 Aug; 17(11):1497-507. PubMed ID: 27254275
[TBL] [Abstract][Full Text] [Related]
11. Muscle and statins: from toxicity to the nocebo effect.
Pedro-Botet J; Climent E; Benaiges D
Expert Opin Drug Saf; 2019 Jul; 18(7):573-579. PubMed ID: 31070941
[TBL] [Abstract][Full Text] [Related]
12. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel.
Banach M; Rizzo M; Toth PP; Farnier M; Davidson MH; Al-Rasadi K; Aronow WS; Athyros V; Djuric DM; Ezhov MV; Greenfield RS; Hovingh GK; Kostner K; Serban C; Lighezan D; Fras Z; Moriarty PM; Muntner P; Goudev A; Ceska R; Nicholls SJ; Broncel M; Nikolic D; Pella D; Puri R; Rysz J; Wong ND; Bajnok L; Jones SR; Ray KK; Mikhailidis DP
Expert Opin Drug Saf; 2015 Jun; 14(6):935-55. PubMed ID: 25907232
[TBL] [Abstract][Full Text] [Related]
13. Statin intolerance - a question of definition.
Algharably EA; Filler I; Rosenfeld S; Grabowski K; Kreutz R
Expert Opin Drug Saf; 2017 Jan; 16(1):55-63. PubMed ID: 27645111
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and Management of Statin Intolerance.
Alonso R; Cuevas A; Cafferata A
J Atheroscler Thromb; 2019 Mar; 26(3):207-215. PubMed ID: 30662020
[TBL] [Abstract][Full Text] [Related]
15. Identification of Patients with Statin Intolerance in a Managed Care Plan: A Comparison of 2 Claims-Based Algorithms.
Bellows BK; Sainski-Nguyen AM; Olsen CJ; Boklage SH; Charland S; Mitchell MP; Brixner DI
J Manag Care Spec Pharm; 2017 Sep; 23(9):926-934. PubMed ID: 28854079
[TBL] [Abstract][Full Text] [Related]
16. World Heart Federation Cholesterol Roadmap 2022.
Ray KK; Ference BA; Séverin T; Blom D; Nicholls SJ; Shiba MH; Almahmeed W; Alonso R; Daccord M; Ezhov M; Olmo RF; Jankowski P; Lanas F; Mehta R; Puri R; Wong ND; Wood D; Zhao D; Gidding SS; Virani SS; Lloyd-Jones D; Pinto F; Perel P; Santos RD
Glob Heart; 2022; 17(1):75. PubMed ID: 36382159
[TBL] [Abstract][Full Text] [Related]
17. Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance.
Koskinas K; Wilhelm M; Windecker S
Swiss Med Wkly; 2016; 146():w14333. PubMed ID: 27400448
[TBL] [Abstract][Full Text] [Related]
18. Statin Intolerance: the Clinician's Perspective.
Stulc T; Ceška R; Gotto AM
Curr Atheroscler Rep; 2015 Dec; 17(12):69. PubMed ID: 26490078
[TBL] [Abstract][Full Text] [Related]
19. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
20. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines.
Steen DL; Khan I; Ansell D; Sanchez RJ; Ray KK
BMJ Open; 2017 Feb; 7(2):e013255. PubMed ID: 28213597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
